Related Experiment Video
Updated: Dec 10, 2025
09:44
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
512
Ketotherapeutics for neurodegenerative diseases
Nicholas G Norwitz1, Javier Gilbert Jaramillo1, Kieran Clarke1
1Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
International Review of Neurobiology
|August 29, 2020
Summary
Alzheimer's and Parkinson's diseases share metabolic issues. Ketone bodies, like d-β-hydroxybutyrate, show promise as a nutritional therapy to address these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Metabolic Disorders
- Neurodegenerative Diseases
Background:
- Alzheimer's disease (AD) and Parkinson's disease (PD) are leading neurodegenerative disorders.
- AD causes memory loss; PD causes motor deficits like tremor and bradykinesia.
- Both diseases share mitochondrial, inflammatory, and metabolic pathologies.
Purpose of the Study:
- To review the intersection of AD and PD pathologies with ketone body metabolism.
- To explore the potential of ketone bodies as an adjunctive nutritional therapy for AD and PD.
Main Methods:
- Literature review focusing on shared pathologies in AD and PD.
- Analysis of ketone body metabolism and signaling pathways.
- Examination of d-β-hydroxybutyrate (βHB) as a therapeutic agent.
Main Results:
- Shared metabolic dysfunctions in AD and PD are identified.
- Ketone bodies, particularly βHB, are implicated in cellular energy and signaling.
- Evidence suggests βHB's potential to mitigate AD and PD pathologies.
Conclusions:
- Ketone bodies represent a potential therapeutic avenue for AD and PD.
- Targeting ketone body metabolism may offer a novel adjunctive nutritional strategy.
- Further research into βHB for neurodegenerative diseases is warranted.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
640
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
640
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
01:29Drugs Affecting Neurotransmitter Synthesis
1.9K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.9K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
424
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
424
01:24Parkinson's Disease: Treatment
815
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
815
01:26Neurochemical Transmission: Sites of Drug Action
3.3K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.3K